T2 Biosystems (TTOO) announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company’s direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems’ sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems’ products provided: faster time to detection, faster targeted therapy, and reduced length of stay. In March 2024, the Company announced the results of a new prospective study that was published in the Journal of Clinical Microbiology, highlighting the performance and clinical benefits of the T2Resistance Panel compared to blood culture and standard microbiology methods, including high accuracy, rapid turnaround time, and clinical impact.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TTOO:
- T2 Biosystems extends multi-year supplier agreement with Vizient
- T2 Biosystems Advances Sepsis Detection Technology Licensing
- T2 Biosystems announces plans to license technology to expand its leadership
- T2 Biosystems Reports Increased Losses and Cash Crunch
- TTOO Earnings this Week: How Will it Perform?